Purpose of review Psychotropic medications are commonly prescribed to people with intellectual disability. We reviewed current evidence-based pharmacotherapy options and recent updates to guide clinicians in their medication management plans.
INTRODUCTION
Mental health and behavioral problems, such as aggression, self-injurious behavior (SIB), attentional problems, depression, and anxiety are common in people with intellectual disability (PWID) [1] . Psychotropic medications are often prescribed to treat these problems, and concerns of overuse and high rates of polypharmacy in this population have been raised [2 && ,3]. These concerns are further complicated by the challenges in obtaining informed consent for PWID. Furthermore, PWID tend to experience adverse events more frequently than the general population when prescribed psychotropic medications [4,5 & ] . Therefore, it is important for clinicians to understand current evidence of pharmacologic interventions, whereas carefully weighing the risk/benefit ratio and alternatives when considering pharmacotherapy.
CURRENT EVIDENCE AND PERTINENT UPDATES
We primarily focused on randomized placebocontrolled trials (RPCTs) with a sample size of 10 or more within the entire study. We also included genetic and other syndromes commonly associated with PWID. We did not include studies conducted exclusively in an autism spectrum disorder (ASD) population, as we reviewed most of these studies [15, 17] . In long-term studies of risperidone, initial prolactin elevation seems to often reduce over time, and sedation did not appear to result in decline in cognitive functioning [15, 17, 31] .
Results from the studies of antipsychotics in adults with intellectual disability (AWID) are equivocal. Three RPCTs showed risperidone was efficacious in improving problem behaviors [10, 18, 19] . However, a more recent large-scale study with three arms showed no significant difference in the outcomes between risperidone, haloperidol, and placebo groups [20] . Furthermore, a recent study showed that controlled discontinuation of antipsychotics prescribed for problem behaviors in PWID resulted in improved behavioral functioning [32] .
Efficacy and safety of aripiprazole in reducing problem behaviors in children with ASD has been well supported by large RPCTs [33] [34] [35] . However, no RPCT of aripiprazole was found in PWID without ASD.
An RPCT of olanzapine in children with ASD (seven out of 11 were CWID) reported efficacy in improving clinical global impression, but resulted in significant weight gain [36] .
Two RPCTs of haloperidol in PWID suggest some benefit in reducing problem behaviors [21, 22] . EPS were commonly reported.
A small randomized placebo-controlled crossover (RPCCO) study showed that body rocking was significantly suppressed, but other problem behaviors were not influenced by chlorpromazine treatment. Chlorpromazine caused noticeable drowsiness in all patients [37] .
For thioridazine, some RPCTs showed only minimal improvement or worsening of problem behaviors [23, 25, 26] and another suggested efficacy in improving some problem behaviors [24] . Nevertheless, the use is limited because of the potential for proarrythmic cardiotoxicity including Torsades de pointes.
Recent randomized placebo-controlled withdrawal studies showed that zuclopenthixol (not marketed in the United States) was superior to placebo in maintaining improved problem behaviors in PWID [27, 28, 30] . Sedation, fatigue, and EPS were common adverse events.
Stimulants and other medications for attention deficit hyperactivity disorder symptoms There is an RPCCO study in four children with fetal alcohol spectrum disorder, which showed methylphenidate was effective in reducing ADHD symptoms [56] . An RPCCO study in children with velocardiofacial syndrome suggested that methylphenidate might improve cognition and ADHD symptoms [45] .
A small RPCCO study with methylphenidate, dextroamphetamine, and placebo suggested that methylphenidate might be more effective and safer than dextroamphetamine in boys with fragile X syndrome (FXS) [46] . Apart from another study which described that dextroamphetamine reduced hyperactivity compared with placebo in a boy with mild intellectual disability [57] , we found no other studies of amphetamine-based agents.
Atomoxetine was effective in reducing ADHD symptoms in children with ASD with/without intellectual disability in recent RPCTs [58, 59] . Somnolence, fatigue, anorexia, nausea, and irritability were common adverse events.
A small RPCCO study showed clonidine was effective in reducing both inattentive and hyperactive/impulsive ADHD symptoms in CWID [51] . Drowsiness, dry mouth, and anorexia were common adverse events.
A small RPCCO of guanfacine in children with developmental disabilities showed benefits in improving hyperactivity and global functioning [52] . A recent large RPCT in children with ASD (63% were with IQ<70) showed that extendedrelease guanfacine was effective in reducing hyperactivity/impulsivity and inattention with a large effect size (1.67) [53] . Drowsiness, fatigue, emotional fragility, and irritability were common adverse events.
Mood stabilizers and antiepileptic drugs
Despite the common clinical use [2
&&
,8], evidence for the efficacy of mood stabilizers and AEDs in PWID is sparse, particularly outside the studies of lithium (Table 3) [60] [61] [62] [63] [64] [65] [66] [67] .
A number of RPCTs showed lithium was efficacious for management of problem behaviors, particularly aggression, in PWID [60] [61] [62] [63] 68] . However, most of these studies used nonvalidated outcome measures. Nausea, diarrhea, headaches and tremors were common adverse events [69] .
Zuclopenthixol Singh (1992) [27] Open-label Â 6 weeks; The results from RPCTs of valproate in ASD populations are mixed [70] [71] [72] ), and no RPCT in PWID without ASD was found. Evidence from openlabel studies suggested valproate might be effective in improving problem behaviors and affective symptoms in PWID [73, 74] . An open-label study in boys with FXS suggested that valproate might be effective in reducing ADHD symptoms [75] . A small RPCT showed that carbamazepine was effective in reducing problem behaviors in AWID [64] .
Antidepressants
The evidence for antidepressant use in PWID is sparse, and overall is discouraging with generally low response rates and high rates of adverse events (Table 3 ) [60] [61] [62] [63] [64] [65] [66] [67] .
An RPCCO study in AWID showed worsening of problem behaviors with imipramine treatment compared with placebo, irrespective of depressive symptoms [65] . An RPCCO study of clomipramine in AWID showed efficacy in improving stereotypy [66] , whereas another RPCCO study did not show efficacy in reducing repetitive SIB [67] . Both clomipramine studies showed high dropout rates (around 30%), because of intolerable adverse events, including seizure, agitation, and aggression.
We found no RPCT of selective serotonin reuptake inhibitors (SSRIs) in PWID without ASD (selected RPCTs in pediatric ASD populations were reviewed in our previous article [6]). Open-label studies of fluoxetine for treatment of problem behaviors, including repetitive and obsessive-compulsive behaviors in PWID, showed mixed results [76] [77] [78] . Their response rates ranged from 11-60%. Deterioration of symptoms and intolerable adverse events, such as irritability, increased aggression, and sleep difficulties commonly occurred. Open-label studies of paroxetine and citalopram in PWID that targeted depressive symptoms reported slightly better response rates and tolerability [79, 80] . Studies in ASD populations suggested that SSRIs might be better tolerated in adults than in children [81 & ]. However, most studies of SSRIs in PWID included both adults and children, and age specific data were seldom reported, therefore, we could not discern whether the tolerability might be age related in this population or not.
Anxiolytics
Although anxiolytics are often used in PWID for treatment of anxiety symptoms and problem behaviors [2 && ], evidence to support their use is sparse. Benzodiazepines may worsen problem behaviors in some PWID [82] , and their long-term use can increase the risk of developing tolerance and withdrawal, as well as potentially negative effects on cognition, which are often documented in elderly with cognitive decline [83] . Results from uncontrolled studies of buspirone for treatment of problem behaviors in AWID are mixed, some reporting improvements [84] [85] [86] while another describing no improvement [87] . Open-label studies suggested that b-blockers might be effective in reducing aggression and SIB in PWID [88] [89] [90] .
Glutamatergic and g-aminobutyric acidergic agents
Several glutamatergic and g-aminobutyric acidergic (GABAergic) agents have been investigated in PWID associated with genetic syndromes, in hopes of modulating a hypothesized excitatory-inhibitory imbalance in the brain. However, the results from RPCTs of these agents have been rather disappointing (Table 4) RPCTs of piracetam and memantine (glutamate receptor modulators) showed mixed results. Piracetam did not show efficacy in improving cognition in Down's syndrome children [94] . For memantine, two RPCTs in Down's syndrome adults did not show efficacy in improving cognitive measures [95, 96] , whereas an RPCT in adults with fragile X-associated tremor/ataxia syndrome demonstrated efficacy in improving verbal memory [97] .
Despite the previous study suggesting benefits in reducing social avoidance in people with FXS [98] , results from two subsequent large RPCTs of arbaclofen (GABA B receptor agonist) did not show efficacy in primary outcome measures [99] .
Cholinergic agents
Agents that increase cholinergic effects, such as acetylcholinesterase inhibitors and L-carnitine/ L-acetylcarnitine [111] , have been investigated for enhancement of cognition in PWID, but they produced mixed results (Table 4) In RPCTs in people with Down's syndrome, and in an RPCT in boys with FXS, donepezil (an acetylcholinesterase inhibitors) failed to separate from placebo in primary cognitive and behavioral outcome measures [100, [102] [103] [104] 106] . Posthoc analyses in these studies, and results from a small RPCT in a Down's syndrome population, suggested donepezil might improve language and adaptive functions [102, 103, 105] . Donepezil was generally well tolerated [101] . RPCTs of L-carnitine and L-acetylcarnitine suggested efficacy in reducing ADHD symptoms in boys with FXS [108, 110] , but did not show efficacy in improving cognitive or behavioral functions in Rett syndrome or Down's syndrome populations [107, 109] .
Endocrinologic agents
Results from recently completed RPCTs of oxytocin on social behavior in ASD population have been mixed, and it appears single-dose administration might be more effective than continuous treatment in improving social behavior [112 & ]. Currently, about a dozen clinical trials of oxytocin in ASD populations are underway [93 & ].
In PWID populations (Table 5 ) [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] , an RPCT showed that single-dose oxytocin administration increased eye gaze in 10 men with FXS (with adaptive functioning 3-5 standard deviations below the norm) [114] . In an RPCT, in adults with PraderWilli syndrome (PWS), single-dose oxytocin administration improved measures of trust in others, problem behaviors, and sadness tendency [113] . However, 8-week treatment of oxytocin did not improve cognitive or behavioral functions in an RPCCO study in a PWS population [115] .
Growth hormone deficiency is common in people with PWS, and some RPCTs suggested that growth hormone therapy might improve cognitive and behavioral functions in this population (Table  5) [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] . One recently published study showed that open-label growth hormone therapy for up to 7 years in children with PWS was well tolerated, and reduced delays in adaptive skills and motor development, even though the drug effects were not detected after 1-2 years of treatment during the RPCT phase [122] .
In RPCTs, melatonin appears to be effective in reducing sleep problems in PWID, and was well tolerated [123, 124] . A large RPCT in neonates with Down's syndrome suggested that thyroxine might have improved motor and mental development [125] ; however, its follow-up study at age 10.7 years did not show benefits in motor or mental development from the early treatment [126] .
Opioid antagonists and other agents
Results from RPCTs of naltrexone in PWID are mixed (Table 6) [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] . Some reported rather robust effects [127, 129] , whereas others reported no separation from placebo in reducing SIB [130] , or deleterious effects on motor development and Rett syndrome progression [128] . Appetite decrease, nausea, tiredness, and sedation were reported adverse events.
Most RPCTs of methylation promoting dietary supplements such as folate and betadine failed to show efficacy in improving cognitive, adaptive, or behavioral functions (Table 6) [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] . A recent RPCT in boys with FXS reported that minocycline was effective in improving problem behaviors associated with ADHD and anxiety [131] .
CONCLUSION
Despite the fact that psychotropic medications are commonly prescribed in PWID, evidence to support their use is very limited.
Antipsychotics, particularly risperidone, have shown to be effective in reducing problem behaviors in CWID. Evidence of their use in AWID is inconsistent. The risk of adverse events, including EPS and metabolic adverse events associated with long-term antipsychotics use is concerning, and needs to be reserved for severely impairing problem behaviors.
Methylphenidate appears effective in reducing ADHD symptoms in PWID. Adverse events, including irritability, appetite suppression, and sleep difficulties are common. Atomoxetine might be effective also, inferring from the evidence in ASD populations. a-Agonists, particularly extendedrelease guanfacine, appear promising but need more studies to draw a conclusion.
Lithium might be effective in reducing problem behaviors in PWID, but many of the studies are outdated and lack methodological rigor. There is insufficient evidence to support use of valproate or anxiolytics, including b-blockers for management of problem behaviors, anxiety, and/or mood symptoms in PWID. Antidepressants are often poorly tolerated in PWID, and evidence to support their use for management of repetitive/stereotypic behaviors or other problem behaviors is weak.
Despite more promising preclinical data, targeted treatment for people with genetic syndromes, including glutamate receptor modulators and arbaclofen for FXS, and donepezil for Down's syndrome, have failed to show consistent efficacy in recent RPCTs. Growth hormone treatment in people with PWS might have benefits in improving cognition and behavior.
Results from RPCTs of oxytocin on social behaviors are mixed, but many more studies are currently underway. Melatonin appears to reduce sleep difficulties in PWID. It seems there might be a subgroup of PWID that responds favorably to naltrexone with reduced SIB, but predictors are unknown. Most ASD, autism spectrum disorder; FXS, fragile X syndrome; IQ, intelligent quotient; PBs, problem behaviors, PWS, Prader-Willi syndrome; QD, once daily; QID, four times daily; RPCCO, randomized placebo-controlled crossover; RPCT, randomized placebo-controlled trials; SIB, self-injurious behavior; TID, three times daily.
RPCTs of dietary supplements did not show benefits on development or behavioral measures. Even with the medications that have evidence for efficacy, safety, and tolerability are generally poorer in PWID relative to those in the general population. Therefore, more pharmacotherapy options for severely impairing symptoms are urgently needed. However, similar to the challenges in ASD populations discussed in our previous review [6] , the wide range of phenotypic and genotypic heterogeneity of intellectual disability, and difficulty measuring drug effects on cognition and mental development, particularly after a short-term treatment, greatly hinder the development of effective drugs.
Continued research in genetic disorders associated with intellectual disability, such as FXS, Down's syndrome, and PWS might further expand our understanding of pathophysiology, and thus help identify endophenotypes of intellectual disability. These types of advances could one day bring more targeted and individualized treatments for PWID.
Clinical guidelines
With the paucity of evidence for pharmacotherapy options for mental health problems in PWID, the following clinical guidelines are recommended:
(1) Intellectual disability is a lifelong disorder, and pharmacotherapy should be considered only as a part of comprehensive multidisciplinary treatment plan (behavioral therapy, special education, living and social skills training, etc.). (2) Clinicians should consider nonpharmacological interventions, including functional behavior analysis, behavioral management, and environmental modifications before considering pharmacotherapy. (3) Pharmacotherapy should be reserved for impairing symptoms where the risks of adverse events are justified. (4) Appropriate informed consent, with thorough discussions of the risk-benefit ratio and alternatives, should be obtained. (5) Target symptoms should be identified for each medication, and treatment efficacy should be tracked regularly with objective outcomes (frequency, duration and severity of the symptoms, and rating scales) (6) 'Start low and go slow' to minimize adverse events and increase tolerability. (7) Monitor adverse events actively and regularly (utilize questionnaires or scales) (8) Minimize polypharmacy to decrease the likelihood of drug-drug interactions, adverse events, and medication noncompliance.
(9) Aim to use the lowest effective dose and consider lowering dose or withdrawing the medication after an extended period of stability (6-12 months). A randomized double-blind placebo controlled trial with a large sample size that showed methylphenidate was effective in reducing ADHD symptoms in children with intellectual disability.
REFERENCES AND RECOMMENDED READING
6. Ji N, Findling R. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Cur Opin Psychiatry 2015; 28:91-101.
